This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
The study identified six peptide candidates that successfully controlled tumors in mice.
Why it matters
This research addresses key challenges in cancer vaccine development, potentially leading to more effective treatments for patients. It sets the stage for future human trials.
How the study worked
The researchers used immunoprecipitation and mass spectrometry to isolate peptides, followed by RNAseq analysis and functional assays to select the best candidates.
What this study cannot tell us
The study was conducted in a murine model, and results may not directly translate to humans. Further validation in clinical settings is needed.
Read the original research
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
eLife, 11
Citation
Feola, Sara; Chiaro, Jacopo; Martins, Beatriz; Russo, Salvatore; Fusciello, Manlio; Ylösmäki, Erkko; Bonini, Chiara; Ruggiero, Eliana; Hamdan, Firas; Feodoroff, Michaela; Antignani, Gabriella; Viitala, Tapani; Pesonen, Sari; Grönholm, Mikaela; Branca, Rui M M; Lehtiö, Janne; Cerullo, Vincenzo. (2022). A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.. eLife, 11. https://doi.org/10.7554/eLife.71156